BACKGROUND: The prognosis and treatment of astrocytomas, which are primary brain tumors, vary depending on the grade of the tumor, necessitating a precise preoperative classification. Magnetic resonance spectroscopy (MRS) provides information about metabolites in tissues and is an emerging noninvasive tool to improve diagnostic accuracy in patients with intracranial neoplasia. OBJECTIVE: To investigate whether ex vivo MRS could differentiate World Health Organization grade II (A-II) and IV astrocytomas (glioblastomas; GBM) and to correlate MR spectral profiles with clinical parameters. METHODS: Patients with A-II and GBM (n = 58) scheduled for surgical resection were enrolled. Tumor specimens were collected during surgery and stored in liquid nitrogen before being analyzed with high-resolution magic angle spinning MRS. The tumors were histopathologically classified according to World Health Organization criteria as GBM (n = 48) and A-II (n = 10). RESULTS: Multivariate analysis of ex vivo proton high-resolution magic angle spinning spectra MRS showed differences in the metabolic profiles of different grades of astrocytomas. A-II had higher levels of glycerophosphocholine and myo-inositol than GBM. The latter had more phosphocholine, glycine, and lipids. We observed a significant metabolic difference between recurrent and nonrecurrent GBM (P < .001). Primary GBM had more phosphocholine than recurrent GBM. A significant correlation (P < .001) between lipid and lactate signals and histologically estimated percentage of necrosis was observed in GBM. Spectral profiles were not correlated with age, survival, or magnetic resonance imaging-defined tumor volume. CONCLUSION: Ex vivo MRS can differentiate astrocytomas based on their metabolic profiles.
BACKGROUND: The prognosis and treatment of astrocytomas, which are primary brain tumors, vary depending on the grade of the tumor, necessitating a precise preoperative classification. Magnetic resonance spectroscopy (MRS) provides information about metabolites in tissues and is an emerging noninvasive tool to improve diagnostic accuracy in patients with intracranial neoplasia. OBJECTIVE: To investigate whether ex vivo MRS could differentiate World Health Organization grade II (A-II) and IV astrocytomas (glioblastomas; GBM) and to correlate MR spectral profiles with clinical parameters. METHODS:Patients with A-II and GBM (n = 58) scheduled for surgical resection were enrolled. Tumor specimens were collected during surgery and stored in liquid nitrogen before being analyzed with high-resolution magic angle spinning MRS. The tumors were histopathologically classified according to World Health Organization criteria as GBM (n = 48) and A-II (n = 10). RESULTS: Multivariate analysis of ex vivo proton high-resolution magic angle spinning spectra MRS showed differences in the metabolic profiles of different grades of astrocytomas. A-II had higher levels of glycerophosphocholine and myo-inositol than GBM. The latter had more phosphocholine, glycine, and lipids. We observed a significant metabolic difference between recurrent and nonrecurrent GBM (P < .001). Primary GBM had more phosphocholine than recurrent GBM. A significant correlation (P < .001) between lipid and lactate signals and histologically estimated percentage of necrosis was observed in GBM. Spectral profiles were not correlated with age, survival, or magnetic resonance imaging-defined tumor volume. CONCLUSION: Ex vivo MRS can differentiate astrocytomas based on their metabolic profiles.
Authors: Christopher Dietz; Felix Ehret; Francesco Palmas; Lindsey A Vandergrift; Yanni Jiang; Vanessa Schmitt; Vera Dufner; Piet Habbel; Johannes Nowak; Leo L Cheng Journal: NMR Biomed Date: 2017-09-15 Impact factor: 4.044
Authors: Jack J A van Asten; Riyas Vettukattil; Tessa Buckle; Sven Rottenberg; Fijs van Leeuwen; Tone F Bathen; Arend Heerschap Journal: J Transl Med Date: 2015-04-09 Impact factor: 5.531
Authors: Victor Ruiz-Rodado; Jeffery R Brender; Murali K Cherukuri; Mark R Gilbert; Mioara Larion Journal: Prog Nucl Magn Reson Spectrosc Date: 2020-12-02 Impact factor: 9.795
Authors: Andreas Korzowski; Nina Weckesser; Vanessa L Franke; Johannes Breitling; Steffen Goerke; Heinz-Peter Schlemmer; Mark E Ladd; Peter Bachert; Daniel Paech Journal: Front Neurol Date: 2021-12-23 Impact factor: 4.003
Authors: Adam Elkhaled; Llewellyn Jalbert; Alexandra Constantin; Hikari A I Yoshihara; Joanna J Phillips; Annette M Molinaro; Susan M Chang; Sarah J Nelson Journal: NMR Biomed Date: 2014-03-05 Impact factor: 4.044